beva

  1. T

    Costs Of Adverse Events In First-Line Metastatic Renal Cell Carcinoma Treatment: Beva

    UroToday.com - The availability of novel and promising targeted therapies for the treatment of patients with metastatic renal cell carcinoma (RCC), such as bevacizumab plus interferon and sunitinib, has meant important increases in options for patients and physicians treating this deadly...
Back
Top